According to Mark Cuban, there are significant anti-competitive practices by major pharmaceutical members who prevent brand manufacturers from offering rebates through Cost Plus Drugs. Cuban alleges these members threaten to remove manufacturers from formularies if they engage with Cost Plus Drugs. This could impact trading strategies related to pharmaceutical stocks, influencing both market dynamics and investor sentiment.